SUPN (Supernus Pharmaceuticals) EPS (Basic): $-0.51 (TTM As of Mar. 2026)


SUPN Supernus Pharmaceuticals Inc SUPN
87 GF Score
Price $45.13
GF Value $40.55
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals EPS (Basic)?

Supernus Pharmaceuticals SUPN +1.53% 87 EPS (Basic) is $-0.51 as of Mar. 2026. GuruFocus rates SUPN with a GF Score™ of 87/100 and a GF Value™ of $40.55 (Modestly Overvalued).

Supernus Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was $-0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.51.

Supernus Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.51.

Supernus Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was $-0.02. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.24.

During the past 12 months, Supernus Pharmaceuticals's average EPS without NRIGrowth Rate was -121.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Supernus Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 85.70% per year. The lowest was -50.70% per year. And the median was 8.20% per year.

Supernus Pharmaceuticals  (NAS:SUPN) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Supernus Pharmaceuticals EPS (Basic) Related Terms

Supernus Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals EPS (Basic) Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.01 1.13 0.02 1.34 -0.68

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 0.40 -0.80 -0.07 -0.04
SUPN
87GF Score
Supernus Pharmaceuticals Inc SUPN
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Supernus Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-38.55-0)/56.451
=-0.68

Supernus Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-2.293-0)/57.648
=-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of $-0.51 mean?
Supernus Pharmaceuticals (SUPN) has a EPS (Basic) of $-0.51 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' EPS (Basic) too high?
Supernus Pharmaceuticals' current EPS (Basic) is $-0.51. Overall, Supernus Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' EPS (Basic) compare to BCRX and PBH?
Supernus Pharmaceuticals' EPS (Basic) of $-0.51 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current EPS (Basic) is $-0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (SUPN) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.55, compared to a current price of $45.13 — trading 11.3% above its estimated fair value. The current EPS (Basic) is $-0.51. Supernus Pharmaceuticals' overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Supernus Pharmaceuticals (SUPN), the current EPS (Basic) is $-0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (SUPN) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $45.13 is trading 11.3% above its estimated GF Value™ of $40.55. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for SUPN:

  • EPS (Basic): $-0.51
  • GF Value™: $40.55 vs. price of $45.13 (11.3% above fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the SUPN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges 0LB2:UKS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
87GF Score

Get the complete analysis for SUPN

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$45.13
Price
$40.55
GF Value